Compromised bioavailable IGF-1 of black men relates favourably to ambulatory blood pressure: The SABPA study

Atherosclerosis

Volumn 233, Issue 1, 2014, Pages 139-144

  Schutte, A E ^a   Schutte, R ^a   Smith, W ^a   Huisman, H W ^a   Mels, C M C ^a   Malan, L ^a   Fourie, C M T ^a   Malan, N T ^a   Van Rooyen, J M ^a   Kruger, R ^a   Conti, E ^b  

^a NORTH WEST UNIVERSITY   (South Africa)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

African; Ambulatory blood pressure; Atherosclerosis; Black; Growth hormone; Insulin like growth factor binding protein 3; Insulin like growth factor 1; Pregnancy associated plasma protein A

Indexed keywords

AFRICAN; AMBULATORY BLOOD PRESSURE; ATHEROSCLEROSIS; BLACK; GROWTH HORMONE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-3; INSULIN-LIKE GROWTH FACTOR-1; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ATHEROSCLEROSIS; BIOLOGICAL AVAILABILITY; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CAROTID INTIMA-MEDIA THICKNESS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A;

EID: 84893828242     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.12.025     Document Type: Article

References (40)

1. Hirai H., Kanaya R., Maeda M., Qungfang D., Ina K., Hayashi T. The role of insulin growth factor on atherosclerosis and endothelial function: the effect on hyperlipidemia and aging. Life Sci 2011, 88:425-431.
2. Andreassen M., Raymond I., Kistorp C., Hildebrandt P., Faber J., Kristensen L.O. IGF1 as predictor of all cause mortality and cardiovascular disease in an elderly population. Eur J Endocrinol 2009, 160:25-31.
3. Fischer F., Schulte H., Mohan S., et al. Associations of insulin-like growth factors, insulin-like growth factor binding proteins and acid-labile subunit with coronary heart disease. Clin Endocrinol (Oxf) 2004, 61:595-602.
4. Kawachi S., Takeda N., Sasaki A., et al. Circulating insulin-like growth factor-1 and insulin-like growth factor binding protein-3 are associated with early carotid atherosclerosis. Arterioscler Thromb Vasc Biol 2005, 25:617-621.
5. Higashi Y., Sukhanov S., Anwar A., Shai S.Y., Delafontaine P. Aging, atherosclerosis, and IGF-1. JGerontol A Biol Sci Med Sci 2012, 67:626-639.
6. Sukhanov S., Higashi Y., Shai S.Y., et al. IGF-1 reduces inflammatory responses, suppresses oxidative stress, and decreases atherosclerosis progression in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2007, 27:2684-2690.
7. Conti E., Carrozza C., Capoluongo E., et al. Insulin-like growth factor-1 as a vascular protective factor. Circulation 2004, 110:2260-2265.
8. Conti E., Musumeci M.B., De G.M., et al. IGF-1 and atherothrombosis: relevance to pathophysiology and therapy. Clin Sci (Lond) 2011, 120:377-402.
9. Zachariah J.P., Xanthakis V., Larson M.G., et al. Circulating vascular growth factors and central hemodynamic load in the community. Hypertension 2012, 59:773-779.
10. Hunt K.J., Lukanova A., Rinaldi S., et al. Apotential inverse association between insulin-like growth factor I and hypertension in a cross-sectional study. Ann Epidemiol 2006, 16:563-571.
11. Izhar U., Hasdai D., Richardson D.M., Cohen P., Lerman A. Insulin and insulin-like growth factor-I cause vasorelaxation in human vessels invitro. Coron Artery Dis 2000, 11:69-76.
12. Wickman A., Jonsdottir I.H., Bergstrom G., Hedin L. GH and IGF-I regulate the expression of endothelial nitric oxide synthase (eNOS) in cardiovascular tissues of hypophysectomized female rats. Eur J Endocrinol 2002, 147:523-533.
13. LeRoith D., Werner H., Beitner-Johnson D., Roberts C.T. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995, 16:143-163.
14. Helle S.I., Ekse D., Holly J.M., Lonning P.E. The IGF-system in healthy pre- and postmenopausal women: relations to demographic variables and sex-steroids. JSteroid Biochem Mol Biol 2002, 81:95-102.
15. Volzke H., Friedrich N., Schipf S., et al. Association between serum insulin-like growth factor-I levels and thyroid disorders in a population-based study. JClin Endocrinol Metab 2007, 92:4039-4045.
16. Sarzi-Puttini P., Atzeni F., Scholmerich J., Cutolo M., Straub R.H. Anti-TNF antibody treatment improves glucocorticoid induced insulin-like growth factor 1 (IGF1) resistance without influencing myoglobin and IGF1 binding proteins 1 and 3. Ann Rheum Dis 2006, 65:301-305.
17. Schutte A.E., van Vuuren D., van Rooyen J.M., et al. Inflammation, obesity and cardiovascular function in African and Caucasian women from South Africa: the POWIRS study. JHum Hypertens 2006, 20:850-859.
18. Schutte A.E., Schutte R., Huisman H.W., et al. Are behavioural risk factors to be blamed for the conversion from optimal blood pressure to hypertensive status in Black South Africans? A 5-year prospective study. Int J Epidemiol 2012, 41:1114-1123.
19. Hamer M., Malan L., Schutte A.E., et al. Conventional and behavioral risk factors explain differences in sub-clinical vascular disease between black and Caucasian South Africans: the SABPA study. Atherosclerosis 2011, 215:237-242.
20. Schutte A.E., Huisman H.W., van Rooyen J.M., et al. Asignificant decline in IGF-I may predispose young Africans to subsequent cardiometabolic vulnerability. JClin Endocrinol Metab 2010, 95:2503-2507.
21. Bayes-Genis A., Schwartz R.S., Lewis D.A., et al. Insulin-like growth factor binding protein-4 protease produced by smooth muscle cells increases in the coronary artery after angioplasty. Arterioscler Thromb Vasc Biol 2001, 21:335-341.
22. Schutte A.E., Schutte R., Huisman H.W., et al. Blood pressure variability is significantly associated with ECG left ventricular mass in normotensive Africans: the SABPA Study. Hypertens Res 2011, 34:1127-1134.
23. Touboul P.J., Hennerici M.G., Meairs S., et al. Mannheim carotid intima-media thickness consensus (2004-2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis 2007, 23:75-80.
24. International standards for antrhopometric assessment 2001, International Society for the Advancement of Kinanthropometry (ISAK), National Library of Australia, Adelaide, p. 133.
25. Hayashi I., Morishita Y., Imai K., Nakamura M., Nakachi K., Hayashi T. High-throughput spectrophotometric assay of reactive oxygen species in serum. Mutat Res 2007, 631:55-61.
26. Lawlor D.A., Ebrahim S., Smith G.D., Cherry L., Watt P., Sattar N. The association of insulin-like-growth factor 1 (IGF-1) with incident coronary heart disease in women: findings from the prospective British Women's Heart and Health Study. Atherosclerosis 2008, 201:198-204.
27. Kaplan R.C., McGinn A.P., Pollak M.N., et al. Association of total insulin-like growth factor-I, insulin-like growth factor binding protein-1 (IGFBP-1), and IGFBP-3 levels with incident coronary events and ischemic stroke. JClin Endocrinol Metab 2007, 92:1319-1325.
28. Martin R.M., Gunnell D., Whitley E., et al. Associations of insulin-like growth factor (IGF)-I, IGF-II, IGF binding protein (IGFBP)-2 and IGFBP-3 with ultrasound measures of atherosclerosis and plaque stability in an older adult population. JClin Endocrinol Metab 2008, 93:1331-1338.
29. Janssen J.A., Stolk R.P., Pols H.A., Grobbee D.E., Lamberts S.W. Serum total IGF-I, free IGF-I, and IGFB-1 levels in an elderly population: relation to cardiovascular risk factors and disease. Arterioscler Thromb Vasc Biol 1998, 18:277-282.
30. Wang J., Razuvaev A., Folkersen L., et al. The expression of IGFs and IGF binding proteins in human carotid atherosclerosis, and the possible role of IGF binding protein-1 in the regulation of smooth muscle cell proliferation. Atherosclerosis 2012, 220:102-109.
31. Shai S.Y., Sukhanov S., Higashi Y., Vaughn C., Rosen C.J., Delafontaine P. Low circulating insulin-like growth factor I increases atherosclerosis in ApoE-deficient mice. Am J Physiol Heart Circ Physiol 2011, 300:H1898-H1906.
32. Sukhanov S., Higashi Y., Shai S.Y., et al. Differential requirement for nitric oxide in IGF-1-induced anti-apoptotic, anti-oxidant and anti-atherosclerotic effects. FEBS Lett 2011, 585:3065-3072.
33. Spence J.D. Ultrasound measurement of carotid plaque as a surrogate outcome for coronary artery disease. Am J Cardiol 2002, 89:10B-15B.
34. Nambi V., Brunner G., Ballantyne C.M. Ultrasound in cardiovascular risk prediction: don't forget the plaque!. JAm Heart Assoc 2013, 2:e000180.
35. Malan N.T., Hamer M., Lambert G.W., et al. Sex hormones associated with subclinical kidney damage and atherosclerosis in South African men: the SABPA study. JHypertens 2012, 30:2387-2394.
36. Pieterse C., Schutte A.E., Mels C., Smith W., Schutte R. Carotid cross-sectional wall area is significantly associated with serum leptin levels, independent of body mass index: the SABPA study. Hypertens Res 2012, 35:1185-1192.
37. Schutte R., Huisman H.W., Malan L., et al. Alkaline phosphatase and arterial structure and function in hypertensive African men: the SABPA study. Int J Cardiol 2013, 167:1995-2001.
38. Schutte R., Schutte A.E., Huisman H.W., et al. Blood glutathione and subclinical atherosclerosis in African men: the SABPA Study. Am J Hypertens 2009, 22:1154-1159.
39. Huisman H.W., Schutte R., Schutte A.E., et al. The usefulness of gamma-glutamyltransferase as a marker of cardiovascular function in Africans and Caucasians: the SABPA study. Clin Exp Hypertens 2012, 34:8-16.
40. Huisman H.W., Schutte A.E., Schutte R., et al. Exploring the link between cardiovascular reactivity and end-organ damage in African and Caucasian men: the SABPA study. Am J Hypertens 2013, 26:68-75.